Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors
- PMID: 17917588
- DOI: 10.1097/nen.0b013e318156bc05
Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors
Abstract
We investigated genetic heterogeneity of astrocytic gliomas using p53 gene mutations as a marker. Different parts of morphologically heterogeneous astrocytic gliomas were microdissected, and direct DNA sequencing of p53 gene exons 5 through 8 was performed. Thirty-five glioma samples and tumor-adjacent normal-appearing brain tissue from 11 patients were analyzed. Sixteen different p53 gene mutations were found in 7 patients. We found that some tumors were devoid of p53 gene mutations, whereas other tumors carried 1 or often several (up to 3) different mutations. The mutations were present in grade II, III, and IV astrocytic glioma areas. Both severe functionally dead mutants and mutants with remaining transcriptional activity could be observed in the same tumor. We observed that morphologically different parts of a glioma could carry different or similar mutations in the p53 gene and could be either associated or not associated with the locus of heterozygosity at the mutant site. Coexistence of p53 gene mutations and the locus of heterozygosity was common, at least in astrocytomas grade III and in glioblastomas, and also occurred in astrocytoma grade II areas. These results support the notion that intratumoral heterogeneity in brain tumors originates from different molecular defects. Our results are of importance for a further understanding of the molecular mechanisms behind failure to treat glioma patients.
Similar articles
-
Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies.Clin Cancer Res. 1997 Apr;3(4):523-30. Clin Cancer Res. 1997. PMID: 9815715
-
Detection of a novel point mutation in the p53 gene in grade II astrocytomas by PCR-SSCP analysis with additional Klenow treatment.Anticancer Res. 2001 Jul-Aug;21(4A):2739-43. Anticancer Res. 2001. PMID: 11724349
-
p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression.Cancer Res. 1992 Feb 1;52(3):674-9. Cancer Res. 1992. PMID: 1346255
-
Progression as exemplified by human astrocytic tumors.Semin Cancer Biol. 1999 Aug;9(4):267-76. doi: 10.1006/scbi.1999.0132. Semin Cancer Biol. 1999. PMID: 10448114 Review.
-
[Histological and molecular classification of gliomas].Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):505-15. doi: 10.1016/j.neurol.2008.03.011. Epub 2008 Jun 10. Rev Neurol (Paris). 2008. PMID: 18565348 Review. French.
Cited by
-
Mutations of the human interferon alpha-2b gene in brain tumor patients exposed to different environmental conditions.Cancer Gene Ther. 2015 May;22(5):246-61. doi: 10.1038/cgt.2015.12. Epub 2015 Apr 3. Cancer Gene Ther. 2015. PMID: 25837663 Review.
-
Direct inhibition of myosin II effectively blocks glioma invasion in the presence of multiple motogens.Mol Biol Cell. 2012 Feb;23(4):533-42. doi: 10.1091/mbc.E11-01-0039. Epub 2012 Jan 4. Mol Biol Cell. 2012. PMID: 22219380 Free PMC article.
-
The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment.J Exp Clin Cancer Res. 2019 Oct 21;38(1):420. doi: 10.1186/s13046-019-1434-2. J Exp Clin Cancer Res. 2019. PMID: 31639020 Free PMC article.
-
The cellular origin for malignant glioma and prospects for clinical advancements.Expert Rev Mol Diagn. 2012 May;12(4):383-94. doi: 10.1586/erm.12.30. Expert Rev Mol Diagn. 2012. PMID: 22616703 Free PMC article. Review.
-
Novel Perspectives on p53 Function in Neural Stem Cells and Brain Tumors.J Oncol. 2011;2011:852970. doi: 10.1155/2011/852970. Epub 2010 Dec 15. J Oncol. 2011. PMID: 21209724 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous